BLADDER CANCER – LATEST CHANGES IN SURGICAL AND MEDICAL THERAPY

Czech version

Authors: J. Bedke; A. Stenzl
Authors‘ workplace: Eberhard Karls University Tuebingen ; Department of Urology
Published in: Urol List 2011; 9(3): 34-39

Overview

New strategies in the treatment of bladder cancer (BC), which were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2010 are highlighted. In non-muscle-invasive bladder cancer gender-specific use of photodynamic diagnostic is discussed and new data of drug-delivery in intravesical therapy are presented. Conventional platinum-based chemotherapy is well established in metastatic BC. Results using new combinatory regimes, which target angiogenesis and VEGF, are presented. New therapy strategies extend the use of chemotherapy also to formerly „unfit“ patients with an impaired renal function or performance status. Special questions of adjuvant therapy and bladder preserving strategies are addressed.

Key words:
bladder cancer, chemotherapy, radiation, photodynamic diagnostic, intravesical therapy, targeted therapy

Sources

1. Barlow LJ, Laudano MA, Mann MJ et al. Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. J Clin Oncol 2010; 28:15s: suppl; abstr 4542.

2. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. J Clin Oncol 2010; 28:15s: suppl; abstr LBA4519.

3. Di Stasi SM, Verri C, Capelli G et al. Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial. J Clin Oncol 2010; 28:15s: suppl; abstr 4543.

4. Galsky MD, Sonpavde G, Hellerstedt BA et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). J Clin Oncol 2010; 28:15s: suppl; abstr 4573.

5. Hahn NM, Stadler WM, Zon R, Waterhouse DM et al. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). J Clin Oncol 2010; 28:15s: suppl; abstr 4541.

6. James ND, Hussain SA, Hall E et al. Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 2010; 28:15s: suppl; abstr 4517.

7. Krause F, Ott O, Haeberle B et al. Validation of a trimodalitiy treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome. J Clin Oncol 2010; 28:15s: suppl; abstr 4575.

8. Krege S, Rexer H, vom Dorp F et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). J Clin Oncol 2010; 28:15s: suppl; abstr 4574.

9. Kruck S, Burger M, Denzinger S et al. Incidence of carcinoma in situ (CIS) and muscle-invasive bladder cancer by gender: Analysis of 600 primary cases at initial presentation. J Clin Oncol 2010; 28:15s: suppl; abstr e15103.

10. Leprini G, Massoud R, Dolci S et al. Con-centration-depth profiles of mitomycin-C in thehuman bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration. J Clin Oncol 2010; 28:15s: suppl; abstr 4568.

11. Lynch SP, Vu TT, Kamat AM et al. The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience. J Clin Oncol 2010; 28:15s: suppl; abstr 4566.

12. Paz-Ares LG, Solsona E, Esteban E et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010; 28:15s: suppl; abstr LBA4529.

13. Quinn DI, Aparicio A, Tsao-Wei DD et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. J Clin Oncol 2010; 28:15s: suppl; abstr 4539.

14. Stenzl A, Cowan NC, De Santis M et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55(4): 815–825.

15. U.S. National Institutes of Health ClinicalTrials (2010). http://www.clinicaltrials.gov/ct2/show/NCT0036515?term=Eribulin&rank=15 gov National Institutes of Health (NIH), Bethesda assessed 10/10/10

16. U.S. National Institutes of Health ClinicalTrials (2010). http://www.clinicaltrials.gov/ct2/show/NCT00821327?term=sunitinib&state1=NA%3AUS%3ANV&rank=12 gov National Institutes of Health (NIH), Bethesda assessed 10/10/10

17. U.S. National Institutes of Health ClinicalTrials (2010). http://www.clinicaltrials.gov/ct2/show/NCT01089088?term=sunitinib+bladder&rank=10 gov National Institutes of Health (NIH), Bethesda assessed 10/10/10

Labels

Paediatric urologist Urology

METHODS OF NON-INVASIVE DIAGNOSTICS AND MONITORING OF URINARY BLADDER CANCER

THE ROLE OF SURGICAL TREATMENT OF SUPERFICIAL BLADDER TUMOUR

INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA

ILEAL NEOBLADDER AND ITS VARIANTS

CHEMOTHERAPY IN INVASIVE AND METASTATIC BLADDER CANCER

Role of botulinum toxin in the management of multiple sclerosis lower urinary tract dysfunctions

EAU Guidelines on non–muscle–invasive urothelial carcinoma of the bladder – the 2011 Update

Treatment of muscle-invasive and metastatic bladder cancer – update of the EAU Guidelines

Article was published in

Urological Journal

2011 Issue 3